Home > Dermatology > AAD 2020 > Spironolactone safe for androgenetic alopecia in cancer survivors

Spironolactone safe for androgenetic alopecia in cancer survivors

The potassium-sparing diuretic spironolactone is a viable treatment option in women with a previous breast cancer diagnosis [1].

In daily practice, spironolactone is often used off-label for the treatment of androgenetic alopecia in women. The agent exerts competitive blockade on androgen receptors in target tissues. It has been shown to arrest hair loss progression; a significant percentage of women even achieve partial hair regrowth [2]. However, limited data is available on its safety in breast cancer survivors. Due to its estrogenic effects, a potential risk for promoting cancer recurrence has been discussed. To clarify this issue, the authors performed a retrospective analysis using the Humana Insurance database.

Breast cancer survivors were identified using ICD-9/10 codes and divided into cohorts by spironolactone prescription. Patient demographics and comorbidities were compared and analysed. Cohorts with and without spironolactone use were f...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on